R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Vice President of Tax

Tax AccountingConfirmed live in the last 24 hours
Full-timeRemote in USA

About the Job

Requirements

  • At least 16 years of progressive corporate tax experience, including preferably 3 or more years of VP of Tax experience with substantial leadership of a global tax function or multiple tax disciplines in a complex multinational.
  • A bachelor's degree in accounting, finance, or a related field, plus a CPA, JD, or equivalent; an advanced degree in taxation or a related field is required.
  • Deep expertise in U.S. corporate and international tax, ASC 740, OECD BEPS, transfer pricing, compliance, and audits.
  • Experience leading tax reporting and controls in a public, SOX-controlled company, partnering with external auditors and senior finance leaders.
  • Success setting functional strategy, building scalable capabilities, and leading complex cross-functional, cross-jurisdictional change, including international expansion.
  • Ability to influence executives, explain complex issues to non-specialists, and manage relationships with tax authorities, auditors, and advisors.
  • A proven record of building high-performing teams and future leaders with clear accountability and a culture of trust, feedback, and collaboration.
  • Enterprise perspective and strong commercial judgment.

Responsibilities

  • Lead the global tax function, owning strategy, operating model, governance, and execution across planning, financial reporting, compliance, and audits.
  • Align tax priorities with long-term corporate strategy, supporting OUS commercial readiness, international expansion, and sustainable growth while protecting financial position and reputation.
  • Advise senior leadership by translating complex tax matters into clear business choices and anticipating risks and opportunities.
  • Build a scalable tax organization and develop leaders, partnering with Finance, Legal, and the business while remaining hands-on in critical judgments and execution.
  • Represent Tax before the Audit Committee and senior executives; the role reports to the Vice President of Finance.
  • Set and own the global tax strategy and multiyear roadmap, aligning priorities, investment, and outcomes with corporate goals, capital needs, and growth.
  • Advise senior leadership on tax implications of strategic decisions, including cash taxes, financial reporting, feasibility, compliance, and reputation; escalate significant exposures to senior executives and, as appropriate, the Audit Committee.
  • Lead tax planning for corporate structure, financing, intellectual property, licensing, collaborations, and transactions; partner with Legal, Treasury, Business Development, and Finance on diligence, structuring, and implementation.
  • Anticipate global tax changes, assess enterprise impact, and lead coordinated responses; establish tax policies, decision rights, and escalation thresholds.
  • Own tax strategy and readiness for new markets with Global Finance and Legal, including entity structures, registrations, operating models, and transition to local support.
  • Lead global transfer pricing policy, intercompany pricing, documentation, and governance, aligned with business substance, intellectual property, supply chain, and local requirements.
  • Partner with Commercial, Supply Chain, Treasury, and others on income tax, indirect tax, tariffs, withholding, and permanent establishment issues in cross-border operations.
  • Own the quality, accuracy, and timeliness of global quarterly and annual tax provisions under U.S. GAAP, including ASC 740 judgments, deferred taxes, valuation allowances, uncertain tax positions, and disclosures.
  • Oversee integration of tax into close processes, forecasts, long-range plans, and cash planning with Corporate Accounting, SEC Reporting, FP&A, and Treasury; explain effective tax rate drivers and material changes.
  • Own tax accounting policies, documentation, and SOX controls; lead external auditor engagement on significant positions and resolve complex reporting matters.
  • Oversee the global tax team managing global compliance across U.S. federal, state, and international obligations; define responsibilities with Payroll, Legal, local Finance, Supply Chain, and service providers.
  • Maximize tax attributes and incentives, including research and development credits and net operating losses.
  • Lead audits, inquiries, and disputes; represent the company with tax authorities and advisors, guide resolution strategy, and escalate significant matters through governance.
  • Set key performance indicators for an integrated tax risk framework, compliance calendar, and monitoring process to identify exposures early and sustain timely filings, payments, and defensible positions.
  • Design and lead the global tax organization, including its internal and external mix; own budget, workforce plan, advisor selection, and provider performance.
  • Recruit, coach, and develop tax leaders; establish succession and development plans, delegate decision-making authority, and hold the team accountable.
  • Lead the tax technology and process roadmap with Finance systems and IT to improve data quality, automation, controls, and integration.
  • Lead cross-functional change by building alignment, clarifying ownership, and ensuring readiness, training, and adoption of new operating models.

Desired Qualifications

  • Biotechnology or pharmaceutical experience, including intellectual property, licensing, and global commercialization.
  • Experience supporting business development transactions, supply chain structures, and the shift from development-stage to broader commercial operations.
  • Experience implementing tax technology and data improvements, and a mix of in-house leadership and public accounting or advisory experience.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs